Teva Bets on Stem Cells, Cancer in $6.2 Billion Cephalon Bid
BusinessWeek Mon, 02 May 2011 13:48 PM PDT
Teva Pharmaceutical Industries Ltd., swooping in to outbid Valeant Pharmaceuticals International Inc. for Cephalon Inc., is betting that “high-risk, high-reward†stem-cell treatments and therapies for asthma and lung cancer can help it overcome growing competition to its biggest product. |
Teva buying Cephalon for $6.8 billion
The Washington Times Mon, 02 May 2011 13:46 PM PDT
NEW YORK (AP) - Teva Pharmaceutical Industries Ltd. has agreed to buy Cephalon Inc. for $6.8 billion in a deal that would give the world's largest generic drug developer a range of biotechnology drugs aimed at cancer and other conditions. Teva, based in Israel, said Monday it will pay $81.50 per ... |
Snow won't hamper 'Purple Ribbon Day'
North Platte Telegraph Mon, 02 May 2011 13:38 PM PDT
The North Platte Telegraph Snow or not, today's Relay For Life activities will continue as planned. North Platte mayor Marc Kaschke officially proclaimed today as "Purple Ribbon Day" to recognize and honor cancer survivors and their caregivers. |
Correction: Pfizer-Earnings Preview story
Seattle Times Mon, 02 May 2011 13:38 PM PDT
In a story April 29 about Pfizer Inc.'s upcoming earnings report, The Associated Press reported erroneously that the drugmaker had received U.S. approval for two cancer drugs, Afinitor and Sutent. Afinitor is made by Novartis AG. |
Karen for a Kause run/walk to benefit breast cancer patients
Suburban Journals Mon, 02 May 2011 13:32 PM PDT
The Karen Weidinger Foundation, a volunteer-based breast cancer foundation located in St. Charles, will present the 6th Annual Karen for a Kause 5K Run, 1 Mile Walk & Children's Mad Dash Against C |
Drug Shortages Imperil Patient Care
Georgia Public Broadcasting Mon, 02 May 2011 13:21 PM PDT
A record number of medicines are in short supply these days. Some of the drugs that are hard to come by include medicines to treat cancer, life-threatening infections and severe pain. read more |
Renal Cancer Drug Temsirolimus Shows Promise Against Mesothelioma
redOrbit Mon, 02 May 2011 13:20 PM PDT
A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology. Temsirolimus, a kinase inhibitor, blocks the action of mammalian target of rapamycin (mTOR), a protein that regulates cell growth, which can slow tumor growth. It's used to treat advanced renal cell ... |
Investigational Agent Shows Promise In Reducing Spread Of Prostate Cancer
redOrbit Mon, 02 May 2011 13:18 PM PDT
A drug developed to treat Ewing's Sarcoma, a rare childhood cancer, may also help prevent human prostate cancer from spreading, as seen in new lab studies say researchers at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center (GUMC). Published online April 29 in PLoS ONE, the researchers report that if the agent continues to work well in further ... |
| |
|